At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 4,018 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Ticagrelor 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
In Brief
A Phase 4 clinical trial evaluating Ticagrelor and Prasugrel for Acute Coronary Syndrome (ACS). Completed, enrolled 4,018 participants across 19 sites in 2 countries.
Detailed Summary
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome (ACS)
CountriesGermany, Italy
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionJul 2019
Study CompletionSep 2021
TodayJul 2026
First PostedSep 18, 2013
Enrollment StartSep 15, 2013
Primary CompletionJul 1, 2019
Study CompletionSep 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 12.8 years ago
Interventions
Ticagrelordrug
Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
Prasugreldrug
Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg